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1. Introduction 
Zonisamide, a 1,2 benzisoxazole derivative is a structurally novel antiepileptic drug (AED) 
with a broad spectrum of antiseizure activity. [1,2 ]Zonisamide has been available in Japan 
since 1989, where it is widely used both as monotherapy and adjunctive therapy (i.e. as Add 
on) for various seizure types and syndromes in adults and children.[3,4]  
In the United States, clinical trials of zonisamide began in the early1980s. These studies 
provided clear evidence of zonisamide’s promise as an effective adjunctive therapy for 
refractory partial seizures. Leppik et al. observed a 52% reduction in seizure frequency in a 
historical-control, open-label, multicenter study. However, development of kidney stones in 
3.7% of patients enrolled in this study led to the temporary termination of US development 
efforts. Testing resumed in the 1990s, and zonisamide was approved by the US Food and 
Drug Administration (FDA) in March 2000 as adjunctive treatment for refractory partial-
onset seizures in adults( aged>16years).5  
Results from placebo-controlled, short-term studies, as well as baseline- or historical-
controlled, long-term studies, demonstrate that zonisamide is an effective adjunctive 
treatment for refractory partial- onset seizures. Zonisamide efficacy did not decline over 
time, suggesting that most patients do not develop tolerance to the anticonvulsant effects of 
zonisamide. Findings from one of the long-term studies indicate that, for some patients, 
zonisamide can be effective as monotherapy.[7] 
Zonisamide was well-tolerated; most adverse events were mild to moderate, and their 
incidence declined as treatment continued. The few serious adverse events were all 
reversible with zonisamide dose reduction or discontinuation or the passage of time. US 
clinical trials show that zonisamide is a safe and effective AED for the treatment of 
refractory partial-onset seizures. Further studies are needed to establish monotherapy 
efficacy in epilepsy. 
The potential use of zonisamide in non epileptic conditions like neuropathic pain, migraine 
prophylaxis [2] and Parkinsonism [6] are briefly touched in this review. 
2. Basic structure and chemistry
58 
1-(1, 2-Benzoxazol-3-yl) methanesulphonamide 
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Molecular Structure 
Molecular Formula C8H8N2O3S 
Molecular Weight 212.23 
Appearance    White powder  
pKa   10.2  
Solubility moderately soluble in water (0.80 mg/mL) 
Melting point 161-163 oC 
Isoelectric Point 10.2  
Phase 1. Metabolising Enzyme (1-st Step of Metabolism)   CYP3A4  
3. Overview of pharmacodynamic properties 
A brief overview of pharmacodynamic properties including mechanism of action is 
discussed here.[1,3, 6] 
Mechanism of action: The precise mechanism is still unclear[5] but various proposed 
mechanisms based on various animal and cellular studies are listed below. 
A. Membrane stabilisation through, 
1. Blockade of voltage-dependent T-type calcium channels and 
2. Blockade of voltage-sensitive sodium channels. 
B. Neuro modulation by 
1. Blockade of potassium-evoked glutamate response  
2. Reduction of glutamate-mediated synaptic excitation  
3. Increased γ -amino butyric acid (GABA) release and 
4. Facilitation of Dopaminergic and serotonergic transmission and 
C. Neuroprotection   By free radical scavenging.[2,3,6] 
Despite the presence of a sulphamoyl group in its chemical structure, zonisamide is only a 
weak inhibitor of carbonic anhydrase [3]and it is 100–200 times less potent than 
acetazolamide[5,8].In contrast to acetazolamide, this effect does not contribute to the 
antiepileptic activity of zonisamide.[8] 
4. Overview of pharmacokinetic properties 
The pharmaco kinetic profile is extensively studied from healthy volunteers from U.S, Japan 
and Europe. The data are published in various reviews [1,3,7.9-12] as well as in conference 
abstracts.[13-16] 
Zonisamide is absorbed relatively rapidly from the gastrointestinal (GI) tract; a peak plasma 
concentration (Cmax) of 3 micrograms/mL was reached 4–5 hours after a 200mg dose in 
healthy volunteers in Japan[17,18].In contrast, Cmax values ranging from 2.3 micrograms/mL 
after a 200mg dose to 12.5 micrograms/mL after an 800mg dose were reached within 2.4–3.6  
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hours in healthy volunteers in the United States.[20].The oral bioavailability of zonisamide is 
100%[19].Food consumption does not influence the extent of zonisamide absorption, 
although the time to Cmax is delayed, occurring at 4–6 hours.[5] 
Zonisamide steady-state plasma concentrations are achieved within 14 days.[5]In patients 
with epilepsy in Japan, zonisamide steady-state plasma concentrations increased linearly 
with increasing dose in the zonisamide dosages of up to 13 mg/kg/day in children and 18.6 
mg/kg/day in adults.[22] On the other hand, zonisamide appeared to demonstrate non 
linear pharmacokinetics in healthy volunteers[20] and patients with epilepsy in the US.[23-25] 
Zonisamide is distributed relatively evenly throughout the whole body; the apparent 
volume of distribution is 1.45 L/kg following a 400mg oral dose[5].The drug is not highly 
bound to plasma proteins (40–60%).However, zonisamide has a high affinity for 
erythrocytes, with concentrations in these cells exceeding those in plasma by 4- to 9-fold in 
healthy volunteers in Japan.[7,18] 
Zonisamide undergoes hepatic metabolism and is primary route of excretion is by the 
kidneys.[5]After oral administration, inactive zonisamide metabolites identified in the urine, 
but not in the plasma, include N-acetyl-zonisamide and the glucuronide conjugate of the 
open isoxazole ring metabolite 2-sulphamoylacetyl phenol (SMAP). Acetylation of 
zonisamide is mediated by N-acetyltransferase,[9] while reduction to SMAP is mediated by 
the cytochrome P450 isoenzyme 3A4.[5] 
Zonisamide has a long terminal elimination half- life (50–68 hours in plasma and 105 hours 
in erythrocytes) after administration of single oral 200–800mg doses in healthy volunteers in 
Japan and/or the US .Overall, 62% of the administered dose was recovered in the urine and 
3% in the faeces. The pharmacokinetics of zonisamide were not altered to a clinically 
significant extent when compared in young (mean age 28 years) and elderly (mean age 69 
years) healthy volunteers suggesting that dosage adjustment is not necessary in patients of 
advanced age. 
Dosing data from a meta-analysis of 1008 patients in Japan (403 children and 605 adults) 
suggest that zonisamide clearance is moderately higher in children than in adults.[57] In a 
single-dose study, the renal clearance of zonisamide decreased with decreasing renal 
function; marked renal impairment was associated with a 35% increase in the zonisamide 
area under plasma concentration curve. The US manufacturers’ prescribing information 
recommends caution, but not dosage adjustment, in patients with hepatic or renal disease. 
5. Therapeutic efficacy 
5.1 Add-on therapy in adults 
A Randomized, Double-blind, Placebo-controlled Study in Patients with Refractory Partial 
Seizures-Martin J. Brodie et al  states that ZNS provides dose-dependent, effective, and 
generally well-tolerated adjunctive therapy in patients with partial seizures 26 
Review of United States and European clinical trials of zonisamide in the treatment of 
refractory partial-onset seizures done by Edward Faught et al 27: Results from placebo-
controlled, short-term studies, as well as baseline- or historical-controlled, long-term 
studies, demonstrate that zonisamide is an effective adjunctive treatment for refractory 
partial- onset seizures. Zonisamide efficacy did not decline over time, suggesting that most 
patients do not develop tolerance to the anticonvulsant effects of zonisamide. Findings from 
one of the long-term studies indicate that, for some patients, zonisamide can be effective as 
monotherapy. Zonisamide was well-tolerated; most adverse events were mild to moderate, 
and their incidence declined as treatment continued. The few serious adverse events were 
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all reversible with zonisamide dose reduction or discontinuation or the passage of time. US 
clinical trials show that zonisamide is a safe and effective AED for the treatment of 
refractory partial-onset seizures. Further studies are needed to establish monotherapy 
efficacy. 
Practical prescribing and long-term efficacy and safety of zonisamide by Ilo E. Leppik et al 
28: A range of clinical studies and extensive clinical experience have demonstrated the long-
term efficacy and tolerability of zonisamide in the treatment of refractory partial seizures. 
Substantial patient benefit is maintained during continued administration of zonisamide, 
including sustained decreases in seizure frequency for many patients and attainment of 
seizure freedom for a substantial number of individuals. Careful patient management can 
optimise these benefits whilst minimising risks of any AEs. Clinical experience in the US 
indicates that the benefits of zonisamide may extend across a range of seizure types. These 
observations suggest that zonisamide is an efficacious and well tolerated treatment option 
for the long-term management of many types of epilepsy. 
Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide - 
William A. Tosches et al29:  In this study, zonisamide, when used as monotherapy or 
concomitant therapy, proved effective as an anticonvulsant and was well tolerated over time.  
According to a Cochrane data base review done in 200530, Zonisamide has efficacy as an 
add-on treatment in people with drug-resistant partial epilepsy. Minimum effective and 
maximum tolerated doses cannot be identified. The trials reviewed were of 12 week 
duration and results cannot be used to confirm longer periods of effectiveness in seizure 
control. The results cannot be extrapolated to monotherapy or to people with other seizure 
types or epilepsy syndromes.  
In four short-term (24 weeks), placebo-controlled trials conducted in the US or Europe (n = 
138–351), once- or twice-daily administration of zonisamide at dosages of >300 mg/day was 
mostly effective in the treatment of patients with medically refractory partial seizures, with 
or without secondary generalisation to tonic-clonic seizures, based on significantly greater 
reductions in median seizure frequency for all partial seizures, for complex partial seizures 
only and for all seizure types. The corresponding responder rates (i.e. patients achieving a 
>50% reduction from baseline in seizure frequency) in zonisamide >400 mg/day recipients 
were generally significantly greater than with placebo. When assessed in two of the above-
mentioned trials, twice-daily administration of zonisamide 100 or 200 mg/day was mostly 
effective in one study, whereas 100 mg/day was not effective in the other. 
Longer term, the antiepileptic efficacy of zonisamide was maintained in patients who 
continued therapy for up to 2 years, with no evidence of tachyphylaxis or pharmacological 
tolerance. 
The efficacy of zonisamide at mean dosages of 5.9–8.8 mg/kg/day was demonstrated in a 
total of 1008 adults or children in Japan with various types of epilepsy mainly refractory to 
treatment who were recruited to a series of predominantly non-comparative clinical trials. 
In the only active comparator-controlled study performed to date, zonisamide (mean dosage 
330 mg/day) was judged to be as effective as carbamazepine (mean dosage 600 mg/day) in 
Japanese patients with predominantly partial epilepsies. 
5.2 Add-on therapy in children 
There has been extensive clinical trial and clinical practice experience with zonisamide 
therapy in Japanese children. Open-label data from pediatric clinical trials conducted in 
Japan suggest that zonisamide is well tolerated and effective against partial- and 
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generalized-onset seizures in children. Despite this wealth of open-label data, no formal 
pharmacokinetic studies and only one well-controlled trial of zonisamide's efficacy and 
safety in Japanese children have been completed to date. No controlled clinical trials of 
zonisamide in children have been completed in the United States or Europe31 
5.3 Monotherapy in children 
Tohru Sekia32 did a study on seventy-seven children with epilepsy (ages 8 months–15 
years) who were treated with zonisamide. Nine patients were withdrawn early because of 
side effects; these patients were included in side effect but not efficacy analyses. Zonisamide 
dosages were initiated at approximately 2 mg/kg per day and adjusted for each patient 
individually to a maximum of 12 mg/kg per day. Among 44 patients with 
cryptogenic/symptomatic partial epilepsy, 36 (82%) became seizure free; 4 (9%) had a ≥50% 
reduction in seizure frequency; and 4 (9%) had no change in seizures with zonisamide 
treatment. Of 11 patients with cryptogenic/symptomatic generalized epilepsy, 10 (91%) 
became seizure free, and 1 experienced no change with zonisamide treatment. Similarly, 4 
patients (100%) with idiopathic partial epilepsy, and 8 of 9 patients (89%) with idiopathic 
generalized epilepsy became seizure free with zonisamide treatment; in the last group, 1 
experienced no change. Thirty patients (39%) reported side effects, including somnolence 
(11.7%), decreased spontaneity (7.8%), anorexia (6.5%), and rash (6.5%). Thus, zonisamide is 
effective for partial seizures with or without secondarily generalized seizures in children 
and should be considered a broad-spectrum antiepilepsy agent. 
There has been extensive clinical trial and clinical practice experience with zonisamide 
therapy in Japanese children. Open-label data from paediatric clinical trials conducted in 
Japan suggest that zonisamide is well tolerated and effective against partial- and 
generalized-onset seizures in children. Despite this wealth of open-label data, no formal 
pharmacokinetic studies and only one well-controlled trial of zonisamide's efficacy and 
safety in Japanese children have been completed to date. No controlled clinical trials of 
zonisamide in children have been completed in the United States or Europe. 
5.4 Monotherapy in adults 
Angus A. Wilfong[33] in his several small, open-label studies have indicated that it may be 
safe and effective as monotherapy. This present chart review study was conducted to 
evaluate the safety and effectiveness of zonisamide monotherapy in a paediatric and young 
adult patient group. Patient records at the Blue Bird Circle Clinic for Paediatric Neurology 
were reviewed to identify patients receiving zonisamide monotherapy. Efficacy was 
assessed from seizure diaries and patients’ subjective evaluations. Safety and tolerability 
were evaluated by analysis of adverse events and change in body weight. The study 
included 131 patients aged 1 to 21.8 years with a broad spectrum of seizure types and 
epilepsy syndromes. A total of 101 patients (77.1%) achieved a 50% or greater decrease in 
seizure frequency, including 39 patients who achieved seizure freedom. Zonisamide 
monotherapy was well tolerated, with three patients (2.3%) discontinuing for adverse 
events. These results support open-label studies from Japan reporting that zonisamide 
monotherapy is safe and effective in paediatric and young adult patients. 
Pooled analyses of open-label studies34 specifically in young adults and/or children showed 
zonisamide to be effective as adjunctive therapy for refractory partial seizures (dosage of 
2.0–18.6 mg/kg/day) and as monotherapy for newly diagnosed or refractory partial 
seizures (dosage of 1–12 mg/kg/day). 
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6. Specific categories of seizures 
1. Post-operative seizures - Zonisamide, an agent with antiepileptogenic, free radical 
scavenging and neuroprotective actions in experimental animals, showed promising 
effects against postoperative epilepsy in a randomized double blind controlled trial.36 
2. Myoclonic epilepsy - zonisamide may be useful in the treatment of patients with PME. 
Studies have found it to be useful in Unverricht-lundborg disease37. 
3. West syndrome 
4. Brain tumour related epilepsy38  
7. Tolerability and adverse effects 
Zonisamide was generally well tolerated as adjunctive therapy in patients (n = 499) with 
refractory partial seizures enrolled in placebo-controlled trials conducted in the US and 
Europe35, and as adjunctive therapy or monotherapy in adults or children in Japan (n = 
1008) with various types of epilepsy recruited in predominantly non-comparative clinical 
trials. The most frequently occurring adverse events common to these studies were 
somnolence, anorexia, ataxia, gastrointestinal discomfort/abdominal pain, mental slowing, 
weight loss and skin rash/itch. 
Adverse events usually occurred early during treatment (within 4 weeks), were generally of 
mild-to-moderate intensity, and decreased with time in the US and European studies. 
Patient tolerability of zonisamide was optimised during slow titration from low initial 
dosages to therapeutic dosages over 4–8 weeks. 
The tolerability profile of zonisamide in a Japanese study was generally similar to that of 
carbamazepine, although anorexia occurred more frequently with zonisamide, and ataxia 
was noted more frequently with carbamazepine. 
Patients mainly in the US and Europe appear to be at increased risk of developing kidney 
stones (incidence equivalent to 18 cases per 1000 patient-years of exposure), while paediatric 
patients, in particular, appear to be at increased risk of zonisamide-associated 
oligohidrosis/hyperthermia (estimated reporting rate 1–2 cases per 10 000 patient-years of 
exposure). 
7.1 Adverse effects 
All seizure medicines affect the amount of activity by brain cells, and carry dose-related 
risks of:  
• fatigue/somnolence (usually within the first month of treatment and at higher doses)  
• psychiatric symptoms  
• depression  
• psychosis  
• cognitive symptoms  
• impaired concentration  
• speech problems (especially word-finding difficulties)  
• psychomotor slowing  
7.2 Allergy and hypersensitivity 
Zonisamide is a sulfonamide medication. Life-threatening allergies to sulfonamide 
medications can occur, including  
• Stevens-Johnson syndrome  
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• toxic epidermal necrolysis  
• aplastic anaemia  
• agranulocytosis  
• other blood dyscrasias  
• fulminant hepatic necrosis  
Zonisamide should be discontinued immediately in any patient with signs of hypersensitivity 
reaction. Any rash that develops during zonisamide treatment should be monitored carefully, 
and discontinuation should be strongly considered. Deaths due to serious rashes have been 
reported. Rash is most common in the first 2-16 weeks of treatment. 
7.3 Metabolic acidosis 
The FDA identified that zonisamide can cause metabolic acidosis in some patients. The 
acidosis is characterized by:  
• Elevated serum chloride and reduced serum bicarbonate  
• Greater apparent risk early in treatment (but it can arise later)  
• Greater risk with increased dose (but acidosis has been observed with doses as low as 
25 mg daily)  
• Children are at greater risk of acidosis than adults.  
Risk factors include  
• Kidney disease  
• Severe respiratory disorders  
• Diarrhoea  
• Ketogenic diet  
• Drug interactions  
Metabolic acidosis may be asymptomatic, but can be accompanied by symptoms of:  
• Hyperventilation  
• Fatigue  
• Anorexia  
• Cardiac arrhythmias  
Identification and treatment of metabolic acidosis is important, because it can increase the 
risk of:  
• Kidney stones  
• Nephrocalcinosis  
• Bone abnormalities (with increased risk of fracture)  
• Growth delay  
• Abnormal foetal development.  
The FDA recommends treatment of acidosis if it occurs:  
• Consider either reducing the dose or discontinuing the drug and modifying the 
patient's anti-epileptic treatment  
• If a patient with metabolic acidosis is to continue on zonisamide, consider treatment 
with alkali. 
7.4 Oligohydrosis/hyperthermia 
Oligohydrosis, characterised by decreased sweating and elevation in body temperature 
above normal, has been noted in rare cases. Risk factors appear to be the paediatric age 
group, a high level of physical activity and a high ambient temperature. The occurrence of 
oligohydrosis during treatment may be related to weak inhibition of carbonic anhydrase by 
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zonisamide as similar effects have been described following treatment with topiramate and 
acetazolamide, which are known to possess this mechanism. Cautioning parents of this rare 
effect, combined with monitoring in warm climates or hot weather, and ensuring that 
patients remain cool and well hydrated, should help to minimise the risk of oligohydrosis 
7.5 Kidney stones 
The rate of new kidney stones is approximately 18 per 1000 patient-years; with a relative 
risk five to nine times that of the general population. The risk of renal stones appears to be 
greater with higher doses and longer duration of treatment. Increased fluid intake is likely 
to reduce the risk of renal stones through limitation of tubular precipitation and aiding 
passage of any calculi, and fluid intake should be encouraged to get specific gravity to 1.010. 
7.6 Appetite/weight loss 
Mean weight loss was <1.7 kg and the majority of weight decreases are <5 kg in pivotal 
studies. The changes in body weight did not appear to be progressive in the clinical trial 
population, and remain stable over periods of up to 2 years. Weight loss has been confirmed 
by clinical experience with women losing more weight than men. Weight loss has been 
observed even when zonisamide is used in conjunction with valproate 
7.7 Suicide  
The FDA has issued a general warning regarding anticonvulsants and suicide, which 
applies to zonisamide. Children (especially adolescents and young adults) taking 
zonisamide should be monitored closely by their parents for any notable changes in 
behaviour that could indicate the emergence or worsening of suicidal thoughts or behaviour 
or depression 
7.8 Teratogenicity 
Women of child bearing potential who are given zonisamide should be advised to use 
effective contraception. Zonisamide was teratogenic in mice, rats, and dogs and 
embryolethal in monkeys when administered during the period of organogenesis. A variety 
of foetal abnormalities, including cardiovascular defects, and embryo-foetal deaths occurred 
at maternal plasma levels similar to or lower than therapeutic levels in humans. These 
findings suggest that the use of Zonisamide Capsules during pregnancy in humans may 
present a significant risk to the foetus. Zonisamide should be used during pregnancy only if 
the potential benefit justifies the potential risk to the foetus  
8. Dosage and administration
39
 
8.1 Infants and children 
Initial: 1-2 mg/kg/day given in two divided doses/day (although in more urgent settings, 
up to 4 mg/kg/d to start may be tolerated)  
Increase by 0.5-1 mg/kg/day every 2 weeks  
Goal dose: 5-8 mg/kg/day  
Max dose: ~12 mg/kg/day  
(Glauser 2002; Leppik, 1999; Oommen, 1999) 
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8.2 Adolescents and adults 
Initial: 100 mg once daily for 1 week, then 200mg once daily  
Titration: Increase in increments of 100 mg/day if needed for seizure control, with a 
minimum of 2 weeks between adjustments  
Usual effective dose: 100-600 mg/day  
There is no evidence of increased benefit with doses >400 mg/day  
Once vs. twice daily dosing:  
Once daily dosing keeps steady-state serum concentrations within 27%  
Twice daily dosing keeps concentrations within 14%  
Patient with an effective dose which is near the maximum tolerated dose may benefit from 
twice daily dosing  
8.3 Dosage adjustment in renal/hepatic disease 
Slower dosage titration and more frequent monitoring are recommended in patients with 
renal or hepatic disease. It should be used with extreme caution if creatinine clearance is less 
than 50 mL/minute.  
8.4 Levels  
Plasma concentrations may be useful; with therapeutic levels usually between: 10-20 
mcg/mL. Higher levels (up to 30 mcg/mL), may improve control, but are associated with 
adverse effects (Oommen, 1999 and Leppik, 1999).  
8.5 Monitoring  
Due to the risk of asymptomatic metabolic acidosis, the FDA recommends measuring serum 
bicarbonate before starting zonisamide and periodically thereafter (even in the absence of 
symptoms)  
9. Current role of ZNS in the therapy of epilepsy 
Zonisamide was approved by the US Food and Drug Administration (FDA) in March 2000 
as adjunctive treatment for partial-onset seizures in adult. In Japan, it is approved for use as 
monotherapy and as adjunctive therapy for children and adults with both generalized and 
partial seizures 
10. Use in non-epileptic indications 
• The drug has recently hypothesized to be useful in autism40. 
• Zonisamide-induces long-lasting recovery of dopaminergic neurons from MPTP-
toxicity. It has been found to be useful in managing impulse control disorders in 
Parkinson's disease41. 
• Zonisamide can be used for migraine prophylaxis in topiramate-intolerant patients. It is 
also used in the preventive treatment of migraine42,43 
• SUNCT syndrome has been found to show response to zonisamide44 
• It is found to be effective in the treatment of alcohol dependence. It reduced ethanol 
self-administration by risky drinkers.45,46  
• Zonisamide ameliorates symptoms of secondary paroxysmal dystonia.48  
• It is used in the treatment of extrapyramidal and psychotic symptoms in patients  
suffering from dementia with lewy bodies50 
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• Zonisamide Combined with Cognitive Behavioural Therapy has been useful in the 
treatment of Binge Eating Disorder53 
• Idiopathic hemifacial spasm has been found to be responsive to zonisamide54 
• Zonisamide is used in the treatment of neuropsychiatric disorders55. 
• Zonisamide suppresses pain symptoms of formalin-induced inflammatory and 
streptozotocin-induced diabetic neuropathy56. 
11. Conclusion 
In conclusion, the new-generation AED zonisamide, either as adjunctive therapy or as 
monotherapy, effectively reduces the frequency of partial seizures, with or without 
secondary generalisation to tonic-clonic seizures, in adults and children with epilepsy. The 
drug is generally well tolerated and, additionally, has a favourable pharmacokinetic profile 
permitting once- or twice-daily administration. Direct head-to-head comparisons with other 
AEDs would be beneficial in fully defining the place of zonisamide in therapy. In the 
meantime, adjunctive therapy or monotherapy with zonisamide is a convenient, useful 
option for the management of partial seizures, including those refractory to other AEDs. 
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